32 results on '"Ding, Zhenbin"'
Search Results
2. A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinoma
3. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures
4. Comprehensive analysis of complement-associated molecular features in hepatocellular carcinoma
5. Whole‐exome sequencing‐based mutational profiling of hepatocellular adenoma malignant transformation to hepatocellular carcinoma
6. Multi-omics characterization reveals the pathogenesis of liver focal nodular hyperplasia
7. A single-arm, multi-center phase II study of tislelizumab combined with lenvatinib and GEMOX as conversion therapy in potentially resectable locally advanced biliary tract cancer (ZSAB-TransGOLP): A primary analysis.
8. ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
9. Integrated single cell and bulk sequencing analysis identifies tumor reactive CXCR6+ CD8 T cells as a predictor of immune infiltration and immunotherapy outcomes in hepatocellular carcinoma
10. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures
11. Emergent hybrid-dual-graft liver transplantation: a life-saving strategy for a patient with inadequate living donor graft during the COVID-19 pandemic
12. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma
13. SQSTM1 /p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial–mesenchymal transition and mitochondrial function maintenance
14. Adjuvant lenvatinib after radical resection in patients with hepatocellular carcinoma (HCC): Preliminary analysis of a prospective, multi-center, single-arm study.
15. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma.
16. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack
17. Genome-Scale CRISPR Screen Identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma
18. Loss of MLKL ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and hepatic stellate cell activation
19. The Effects of Employee Volunteering on Organizational Loyalty: The Moderating Effects of Perceived Organization Support
20. The Influence of Illegitimate Tasks on the Intention to Continue Volunteering: A Moderated Mediation Model
21. SQSTM1/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial–mesenchymal transition and mitochondrial function maintenance.
22. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack.
23. SQSTM1/p62 in Intrahepatic Cholangiocarcinoma Promotes Tumor Progression Via Epithelial-Mesenchymal Transition and Mitochondrial Function Maintenance
24. Groundwater Quality and Potential Human Health Risk Assessment for Drinking and Irrigation Purposes: A Case Study in the Semiarid Region of North China
25. miR-20a-5p/TGFBR2 Axis Affects Pro-inflammatory Macrophages and Aggravates Liver Fibrosis
26. Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: IS ICC ‐applied prediction model
27. Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: ISICC‐applied prediction model.
28. Coagulopathy associated with poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection
29. The nanomechanical signature of liver cancer tissues and its molecular origin
30. Integrated single cell and bulk sequencing analysis identifies tumor reactive CXCR6 + CD8 T cells as a predictor of immune infiltration and immunotherapy outcomes in hepatocellular carcinoma.
31. LINC00355 triggers malignant progression of hepatocellular carcinoma via the sponge effect on miR-217-5p with the involvement of the Wnt/β-catenin signaling.
32. LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.